Assessment of myocardial viability using delayed enhancement magnetic resonance imaging at 3.0 Tesla

Investigative Radiology

Volumn 41, Issue 9, 2006, Pages 661-667

  Klumpp, Bernhard ^a   Fenchel, Michael ^a   Hoevelborn, Tobias ^a   Helber, Uwe ^a   Scheule, Albertus ^a   Claussen, Claus ^a   Miller, Stephan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

3.0 T; Contrast media; Delayed enhancement; High field magnetic resonance imaging; Myocardial infarction; Myocardial viability

Indexed keywords

ADULT; AGED; ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; FEMALE; HEART FUNCTION; HEART INFARCTION; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MALE; MYOCARDIAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIGNAL NOISE RATIO; STEADY STATE FREE PRECESSION SEQUENCE;

EID: 33747054782     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000233321.82194.09     Document Type: Article

References (34)

1. Heart Disease and Stroke Statisitcs - 2005 Update. Dallas: American Heart Association; 2004.
2. Hurst W. The Heart, Arteries and Veins. 10th ed. New York: McGraw-Hill; 2002.
3. Pagley PR, Beller GA, Watson DD, et al. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation. 1997;96:793-800.
4. Schwaiger M, Pirich C. Positron emission tomography. Z Kardiol. 2000;89:59-66.
5. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;19:1992-2002.
6. Ansari M, Araoz PA, Gerard SK, et al. Comparison of late enhancement cardiovascular magnetic resonance and thallium SPECT in patients with coronary disease and left ventricular dysfunction. J Cardiovasc Magn Reson. 2004;6:549-556.
7. Sakuma H. Optimal use of contrast medium in contrast enhanced MR imaging of the heart. Nippon Igaku Hoshasen Gakkai Zasshi. 2002;62:682-689.
8. Rehwald WG, Fieno DS, Chen EL, et al. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. Circulation. 2002;105:224-229.
9. Miller S, Eckstein FS, Vogel U, et al. The MR signal behavior of a 4-week-old occlusive myocardial infarct in an animal experiment. Fortschr Rontgenstr. 2000;172:527-533.
10. Van Dijkman PR, Hold KM, van der Laarse A, et al. Sequential analysis of infarcted and normal myocardium in piglets using in vivo gadolinium-enhanced MR images. Magn Reson Imaging. 1993;11:207-218.
11. Fieno DS, Kim RJ, Chen EL, et al. Contrast enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. J Am Coll Cardiol. 2000;36:1985-1991.
12. Hunold P, Brandt-Mainz K, Freudenberg L, et al. Evaluation of myocardial viability with contrast-enhanced magnetic resonance imaging-comparison of late enhancement technique with positron emission tomography. Fortschr Rontgenstr. 2002;174:867-873.
13. Depre C, Vanoverschelde JL, Melin JA, et al. Structural and metabolic correlates of the reversibility of chronic left ventricular ischemic dysfunction in humans. Am J Physiol. 1995;268:H1265-H1275.
14. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445.
15. Juergens KU, Wichter T, Renger B, et al. MRI study of left ventricular function in patients with coronary disease and myocardial dysfunction before and after coronary revascularization. Fortschr Rontgenstr. 2001;173:211-217.
16. Kloner RA, Przyklenk K. Hibernation and stunning of the myocardium. N Engl J Med. 1991;325:1877-1879.
17. Greenman RL, Shirosky JE, Mulkern RV, et al. Double inversion black-blood fast spin-echo imaging of the human heart: a comparison between 1.5 T and 3.0 T. J Magn Reson Imaging. 2003;17:648-655.
18. Schar M, Kozerke S, Fischer SE, et al. Cardiac SSFP imaging at 3 Tesla. Magn Reson Med. 2004;51:799-806.
19. Larsson EM, Stahlberg F. 3 Tesla magnetic resonance imaging of the brain. Better morphological and functional images with higher magnetic field strength. Lakartidningen. 2005;102:460-463.
20. Rinck PA, Muller RN. Field strength and dose dependence of contrast enhancement by gadolinium-based MR contrast agents. Eur Radiol. 1999;9:998-1004.
21. Huber A, Bauner K, Wintersberger BJ, et al. Phase-sensitive inversion recovery (PSIR) single-shot TrueFISP for assessment of myocardial infarction at 3 Tesla. Invest Radiol. 2006;41:148-153.
22. Gutberlet M, Noeske R, Schwinge K, et al. Comprehensive cardiac magnetic resonance imaging at 3. 0 Tesla: feasibility and implications for clinical applications. Invest Radiol. 2006;41:154-167.
23. Thulborn KR. Clinical rationale for very-high-field (3.0 Tesla) functional magnetic resonance imaging. Top Magn Reson Imaging. 1999;10:37-50.
24. Robitaille PM, Abduljalil AM, Kangarlu A. Ultra high resolution imaging of the human head at 8 Tesla: 2K x 2K for Y2K. J Comput Assist Tomogr. 2000;24:2-8.
25. Cerqueira MD, Weissman NJ, Dilsizian V, et al. American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart. A Statement for Healthcare Professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539-542.
26. Gutberlet M, Schwinge K, Freyhardt P, et al. Influence of high magnetic field strengths and parallel acquisition strategies on image quality in cardiac 2D CINE magnetic resonance imaging: comparison of 1.5 T vs. 3.0 T. Eur Radiol. 2005;15:1586-1597.
27. Lima JA, Judd RM, Bazille A, et al. Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms. Circulation. 1995;92:1117-1125.
28. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54:1496-1508.
29. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97:765-772.
30. Helak JW, Reichek N. Quantitation of left ventricular mass and volume by two-dimensional echocardiography: in vitro anatomic validation. Circulation. 1981;63:1398-1407.
31. Weyman AE. Principles and practice of echocardiography. Philadelphia: Lea & Febriger; 1994;1335.
32. Kim RJ, Shah DJ. Fundamental concepts in myocardial viability assessment revisited: when knowing how much is "alive" is not enough. Heart. 2004;90:137-140.
33. Mahrholdt H, Wagner A, Parker M, et al. Relationship of contractile function to transmural extent of infarction in patients with chronic coronary artery disease. J Am Coll Cardiol. 2003;42:505-512.
34. Cameron AA, Davis KB, Rogers WJ. Recurrence of angina after coronary artery bypass surgery: predictors and prognosis (CASS Registry). Coronary Artery Surgery Study. J Am Coll Cardiol. 1995;26:895-899.